log in
Print | Back

Haynes and Boone, LLP

Neil Issar

Neil Issar

Associate

Haynes and Boone, LLP
Texas, U.S.A.

tel: +1 214 651 5281
Send an Email

Local Time: Sun. 02:12

Profile
Neil Issar is an associate in the Litigation Practice Group in the Dallas office of Haynes and Boone.

His practice focuses on government investigations, white collar defense, fraud and abuse laws, navigation of regulatory and compliance issues involving the healthcare industry, and the defense of healthcare and other clients in litigation.

At Vanderbilt Law School, Neil worked as a research assistant for multiple professors, conducting independent studies on the detection and prosecution of healthcare fraud and the admissibility of statistical proof in medical reimbursement coding cases. Before law school, Neil gained experience in medical research, designing and directing various patient-centered clinical trials and health policy studies.

Education

J.D., Vanderbilt University Law School, 2016, Vanderbilt Journal of Entertainment & Technology Law, Articles Editor
B.S., McGill University, 2010
Articles

Health Law Vitals - A Healthcare Newsletter from Haynes and Boone, May 2018
Haynes and Boone, LLP, May 2018

View a PDF of the May 2018 edition of the Haynes and Boone Health Law Vitals newsletter. Healthcare Hazards Involving Medical Records During Bankruptcy Companies in the healthcare industry face many unique challenges when undergoing a bankruptcy, including challenges arising due to the federal and state law framework governing the use and disclosure of medical information. In February 2018, the U.S...

Health Law Vitals - A Healthcare Newsletter from Haynes and Boone, March 2018
Haynes and Boone, LLP, March 2018

 More than two and a half years after the U.S. Food and Drug Administration (FDA) announced that it was reevaluating its regulatory framework for homeopathic products, the FDA released its Draft Guidance on Drug Products Labeled as Homeopathic. The Draft Guidance summarizes the FDA’s current enforcement perspective on homeopathic products and provides a list of the FDA’s enforcement priorities.The bills reawakened a debate about the pros and cons of POHs...

FDA Draft Guidance Proposes Risk-Based Regulatory Scheme for Drug Products Labeled as Homeopathic
Haynes and Boone, LLP, March 2018

More than two and a half years after the U.S. Food and Drug Administration (FDA) announced that it was re-evaluating its regulatory framework for homeopathic products, the FDA released its Draft Guidance on Drug Products Labeled as Homeopathic. The Draft Guidance summarizes the FDA’s current enforcement perspective on homeopathic products and provides a list of the FDA’s enforcement priorities...

WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | DISCLAIMER |  © World Services Group, 2018